Arbutus Biopharma Corporation

LSE:0SGC Stock Report

Market Cap: US$665.1m

Arbutus Biopharma Valuation

Is 0SGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0SGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0SGC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0SGC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0SGC?

Key metric: As 0SGC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0SGC. This is calculated by dividing 0SGC's market cap by their current book value.
What is 0SGC's PB Ratio?
PB Ratio6.2x
BookUS$106.89m
Market CapUS$665.12m

Price to Book Ratio vs Peers

How does 0SGC's PB Ratio compare to its peers?

The above table shows the PB ratio for 0SGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.7x
OXB Oxford Biomedica
6.7x93.2%UK£442.5m
PRTC PureTech Health
1.6x-13.0%UK£409.9m
GNS Genus
2.1x37.7%UK£1.1b
BVXP Bioventix
16.3xn/aUK£195.7m
0SGC Arbutus Biopharma
6.2x11.7%US$665.1m

Price-To-Book vs Peers: 0SGC is good value based on its Price-To-Book Ratio (6.2x) compared to the peer average (6.7x).

Price to Book Ratio vs Industry

How does 0SGC's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
0SGC 6.2xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0SGC is expensive based on its Price-To-Book Ratio (6.2x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0SGC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0SGC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0SGC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0SGC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.48
US$5.21
+50.1%
18.9%US$7.02US$3.99n/a5
Nov ’25US$3.94
US$5.01
+27.4%
21.8%US$7.01US$4.02n/a5
Oct ’25US$3.80
US$5.07
+33.7%
21.1%US$7.01US$4.08n/a5
Sep ’25US$3.80
US$4.60
+21.1%
10.6%US$5.00US$4.00n/a5
Aug ’25US$3.75
US$4.57
+22.1%
10.9%US$4.99US$3.95n/a5
Jul ’25US$3.14
US$4.39
+40.0%
11.1%US$5.00US$3.98n/a5
Jun ’25US$3.31
US$4.40
+33.0%
11.2%US$5.01US$4.00n/a5
May ’25US$2.72
US$4.41
+61.8%
11.1%US$5.01US$4.00n/a5
Apr ’25US$2.60
US$4.39
+69.3%
11.4%US$5.01US$3.95n/a5
Mar ’25US$2.77
US$4.39
+58.9%
11.4%US$5.01US$3.95n/a5
Feb ’25US$2.38
US$4.68
+97.0%
16.9%US$6.02US$4.00n/a5
Jan ’25US$2.50
US$4.60
+83.9%
17.4%US$6.00US$3.99n/a5
Dec ’24US$2.05
US$4.60
+124.8%
17.4%US$6.00US$3.99n/a5
Nov ’24US$1.81
US$4.60
+154.8%
17.3%US$6.00US$4.00US$3.945
Oct ’24US$2.00
US$4.60
+130.0%
17.3%US$6.00US$4.00US$3.805
Sep ’24US$2.03
US$5.39
+165.6%
14.8%US$5.99US$3.99US$3.805
Aug ’24US$2.18
US$5.43
+149.6%
14.4%US$6.06US$4.06US$3.755
Jul ’24US$2.23
US$5.44
+143.9%
14.1%US$6.02US$4.08US$3.145
Jun ’24US$2.53
US$5.43
+114.7%
15.0%US$6.09US$4.01US$3.315
May ’24US$2.50
US$5.42
+117.0%
14.8%US$6.03US$4.02US$2.725
Apr ’24US$3.09
US$5.41
+75.1%
14.9%US$6.04US$4.01US$2.605
Mar ’24US$2.70
US$5.35
+98.2%
15.1%US$6.00US$3.96US$2.775
Feb ’24US$2.92
US$5.35
+83.6%
15.1%US$6.00US$3.96US$2.385
Jan ’24US$2.32
US$5.35
+130.9%
15.0%US$6.00US$3.97US$2.505
Dec ’23US$2.33
US$5.43
+132.9%
14.8%US$6.06US$4.04US$2.055
Nov ’23US$2.40
US$6.03
+151.6%
30.8%US$8.99US$3.74US$1.815

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%